NCT02153905 2019-06-17T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 PositiveNational Institutes of Health Clinical Center (CC)Phase 1/2 Terminated3 enrolled 14 charts